GLP-1 Receptor Agonist Therapy With and Without SGLT2 Inhibitors in Patients With Type 2 Diabetes-Reference-Cited by-同舟云学术

GLP-1 Receptor Agonist Therapy With and Without SGLT2 Inhibitors in Patients With Type 2 Diabetes

Published:2023-08 Issue:6 Volume:82 Page:517-525
ISSN:0735-1097
Container-title:Journal of the American College of Cardiology
language:en
Short-container-title:Journal of the American College of Cardiology

Author:

Neves João Sérgio^ORCID,Borges-Canha Marta,Vasques-Nóvoa Francisco,Green Jennifer B.,Leiter Lawrence A.,Granger Christopher B.,Carvalho Davide,Leite-Moreira Adelino,Hernandez Adrian F.,Del Prato Stefano,McMurray John J.V.^ORCID,Ferreira João Pedro

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference26 articles.

1. Diabetes mellitus-related all-cause and cardiovascular mortality in a national cohort of adults;Raghavan;J Am Heart Assoc,2019

2. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials;Zelniker;Lancet,2019

3. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials;Sattar;LANCET DIABETES ENDOCRINOL,2021

4. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD);Davies;Diabetologia,2022

5. Efpeglenatide and clinical outcomes with and without concomitant sodium-glucose cotransporter-2 inhibition use in type 2 diabetes: exploratory analysis of the AMPLITUDE-O trial;Lam;Circulation,2022

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diabetes as a risk factor for MASH progression;Diabetes Research and Clinical Practice;2024-11

2. Glycaemic control is still central in the hierarchy of priorities in type 2 diabetes management;Diabetologia;2024-08-19

3. Glucagon-Like Peptide-1 Receptor Agonists and Atrial Fibrillation Recurrence After Ablation;JACC: Clinical Electrophysiology;2024-08

4. Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials;The Lancet Diabetes & Endocrinology;2024-08

5. SGLT2 inhibitors and GLP-1 receptor agonists: the definitive combination?;The Lancet Diabetes & Endocrinology;2024-08